JB Chemicals & Pharmaceuticals Ltd announced its financial results for the fourth quarter of FY26, revealing a revenue of ₹904 crore and a net profit after tax of ₹101 crore, marking a 30% decline compared to the same quarter last year. The company reported an EBITDA of ₹241 crore, maintaining a margin of 27%, while gross margins stood at 70%. Adjusted net profit after tax, accounting for non-cash ESOP charges and other exceptional items, was ₹150 crore.
The India business segment showed a modest growth of 2% year-on-year, reaching ₹526 crore for the quarter and 9% for the full fiscal year, totalling ₹2,461 crore. The chronic portfolio outperformed with a 19% growth against the industry’s 14%, as per IQVIA MAT March 2026 data.
International formulations reported a 9% decline in revenue for the quarter, amounting to ₹259 crore, while the full year saw a 2% increase, reaching ₹1,154 crore. The decline was attributed to inventory rationalisation and shipment delays due to container constraints.
The CDMO segment experienced a 22% decline in quarterly revenues due to a high base effect from the previous year, while full-year revenues remained flat at ₹445 crore.
The company is undergoing a post-acquisition integration phase, aligning business policies and practices with its parent company. Despite the revenue impact in Q4, JB Chemicals saw significant improvements in gross and EBITDA margins due to cost synergies.
Looking ahead, JB Chemicals expects business performance to improve progressively from April onwards, with core business performance remaining robust despite operational realignment.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).